Your browser doesn't support javascript.
loading
Case report: A gain-of-function of hamartin may lead to a distinct "inverse TSC1-hamartin" phenotype characterized by reduced cell growth.
Praticò, Andrea D; Falsaperla, Raffaele; Comella, Mattia; Belfiore, Giuseppe; Polizzi, Agata; Ruggieri, Martino.
Afiliação
  • Praticò AD; Unit of Clinical Paediatrics, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Falsaperla R; Units of Neonatology and Neonatal Intensive Care and Paediatrics and Paediatric Emergency, Azienda Ospedaliero Universitaria "Policlinico", Catania, Italy.
  • Comella M; Unit of Clinical Paediatrics, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Belfiore G; Unit of Paediatric Radiology, Department of Radiodiagnostics, Azienda Ospedaliero Universitaria "Policlinico", Catania, Italy.
  • Polizzi A; Chair of Paediatrics, Department of Educational Sciences, University of Catania, Catania, Italy.
  • Ruggieri M; Unit of Clinical Paediatrics, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Front Pediatr ; 11: 1101026, 2023.
Article em En | MEDLINE | ID: mdl-37063680
ABSTRACT
Mutations of TSC1 and TSC2 genes cause classical Tuberous Sclerosis Complex (TSC), a neurocutaneous disorder characterized by a tendency to develop hamartias, hamartomas, and other tumors. We herein report on a girl, now aged 5 years, who presented a previously unreported, distinct clinical phenotype consisting of primary microcephaly (head circumference = 40 cm, -5.6 standard deviations), brain anomalies including hypoplasia of the corpus callosum (with a residual draft of the genu), simplified parieto-temporal gyral pattern, colpocephaly with ectasia of the temporal ventricular horns, intellectual disability, and a general pattern of reduced growth (with weight and height < 3rd centiles). No classical features of TSC were recorded; the girl harbored a novel missense variant in TSC1 (c.611G > A). We hypothesize that her clinical phenotype could be related to a "gain-of-function" of the TSC1 protein product hamartin, causing an increase in the effects of the protein on inhibition of its intracellular targets (i.e., mTORC or RAC1 pathways), resulting in a distinct "inverse TSC1-hamartin" phenotype characterized by reduced growth of cells instead of the more classical predisposition to increased cell growth.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article